Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 5, 2010 - Issue 2
Submit an article Journal homepage
42
Views
0
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Increased fracture risk in patients treated with thiazolidinediones: the role of abnormal bone turnover

Mark Cooper Senior Clinical Lecturer in Endocrinology, The Institute of Biomedical Research, University of Birmingham, Birmingham B15 2TH, UK. [email protected]
Pages 177-180 | Published online: 10 Jan 2014

References

  • Zinman B, Haffner SM, Herman WH et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab.95(1), 134–142 (2010).
  • Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA295(13), 1549–1555 (2006).
  • de Laet C, Kanis JA, Oden A et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos. Int.16(11), 1330–1338 (2005).
  • Kinjo M, Setoguchi S, Solomon DH. Bone mineral density in adults with the metabolic syndrome: analysis in a population-based US sample. J. Clin. Endocrinol. Metab.92(11), 4161–4164 (2007).
  • Reid IR. Relationships between fat and bone. Osteoporos. Int.19(5), 595–606 (2008).
  • Nankaku M, Kanzaki H, Tsuboyama T, Nakamura T. Evaluation of hip fracture risk in relation to fall direction. Osteoporos. Int.16(11), 1315–1320 (2005).
  • Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of Type 1 and Type 2 diabetes mellitus and risk of fracture. Am. J. Epidemiol.166(5), 495–505 (2007).
  • Holmberg AH, Nilsson PM, Nilsson JA, Akesson K. The association between hyperglycemia and fracture risk in middle age. A prospective, population-based study of 22,444 men and 10,902 women. J. Clin. Endocrinol. Metab.93(3), 815–822 (2008).
  • Leslie WD, Lix LM, Prior HJ, Derksen S, Metge C, O’Neil J. Biphasic fracture risk in diabetes: a population-based study. Bone40(6), 1595–1601 (2007).
  • de L II, van der KM, De Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in Type-2 diabetes mellitus: the Rotterdam Study. Osteoporos. Int.16(12), 1713–1720 (2005).
  • Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J. Bone Miner. Res.22(9), 1317–1328 (2007).
  • Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med.355(23), 2427–2443 (2006).
  • Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos. Int.19(2), 129–137 (2008).
  • Akune T, Ohba S, Kamekura S et al. PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest.113(6), 846–855 (2004).
  • Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology148(6), 2669–2680 (2007).
  • Grey A, Bolland M, Gamble G et al. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab.92(4), 1305–1310 (2007).
  • Wan Y, Chong LW, Evans RM. PPAR-γ regulates osteoclastogenesis in mice. Nat. Med.13(12), 1496–1503 (2007).
  • Cooper MS. Sensitivity of bone to glucocorticoids. Clin. Sci. (Lond.)107(2), 111–123 (2004).
  • Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J. Bone Miner. Res.21(8), 1215–1223 (2006).
  • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med.356(24), 2457–2471 (2007).
  • Chia CW, Egan JM. Incretin-based therapies in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab.93(10), 3703–3716 (2008).
  • Yamada C, Yamada Y, Tsukiyama K et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology149(2), 574–579 (2008).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.